Performance of the disease risk score in a cohort study with policy-induced selection bias
Tadrous M, Mamdani MM, Juurlink DN, Krahn MD, Levesque LE, Cadarette SM. J Comp Eff Res. 2015; 4(6):607-14. Epub 2015 Nov 3.
Publications
Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study
Fraser LA, Albaum JM, Tadrous M, Burden AM, Shariff SZ, Cadarette SM. CMAJ Open. 2015; 3(1):E91-96.
Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access
Burden AM, Tadrous M, Calzavara A, Cadarette SM. Osteoporos Int. 2015; 26(5):1525-33. Epub 2015 Jan 21.
Initial uptake of the Ontario Pharmacy Smoking Cessation Program
Wong L, Burden AM, Liu YY, Tadrous M, Pojskic N, Dolovich L, Calzavara A, Cadarette SM. Can Pharm J. 2015; 148(1):29-40. Epub 2014 Dec 17.
Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study
Cadarette SM, Levesque L, Mamdani M, Perreault S, Juurlink DN, Paterson JM, Carney G, Gunraj N, Hawker GA, Tadrous M, Wong L, Dormuth CR. CMAJ Open. 2013; 1(3):E97-105.
Variation in the days supply field for osteoporosis medications in Ontario
Burden AM, Huang A, Tadrous M, Cadarette SM. Arch Osteoporos. 2013; 8:128. Epub 2013 Mar 9.